International clinical trial at K+31 West

An international randomized double-blind clinical trial of immunotherapy (BCD-100 drug) versus placebo in the first line of metastatic (stage IVB) or recurrent (after radical treatment) cervical cancer has started at the department of antitumor drug therapy of the K+31 West clinic.

The study is taking place in Russia and China in more than 50 clinical centers.

In the study 2 sleeves:

In the first arm, patients receive paclitaxel+carboplatin+bevacizumab+BCD100 for 6 courses and then maintenance therapy with bevacizumab and BCD-100.

In the second arm, patients receive paclitaxel+carboplatin+bevacizumab+placebo for 6 courses and then maintenance therapy with bevacizumab and placebo.

• The study included patients with histologically verified stage IVB squamous cell, glandular and glandular cell carcinoma of the cervix, or with a recurrence after radical treatment in a satisfactory general condition (ECOG 0-1) and without significant comorbidities.
• Patients who received drug treatment in connection with stage IVB cervical cancer or with relapse after radical treatment are not allowed, and patients with contraindications to the use of these chemo- and targeted drugs are also not allowed.
• It is necessary to have histological material (paraffin blocks) on the hands. In the absence of material, it is necessary to conduct a biopsy of the accessible tumor focus.

This study is completely free for all Russian citizens without reference to the region.

The contact person is the principal investigator Satirova Elena Fedorovna, head of the department of antitumor drug treatment at the K+31 West clinic, an oncologist of the highest category.